| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027031 | TELIX | Kit for radiolabelling |
Jul, 2035
(11 years from now) | |
Illuccix is owned by Telix.
Illuccix contains Gallium Ga-68 Gozetotide.
Illuccix has a total of 1 drug patent out of which 0 drug patents have expired.
Illuccix was authorised for market use on 17 December, 2021.
Illuccix is available in powder;intravenous dosage forms.
Illuccix can be used as positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer.
The generics of Illuccix are possible to be released after 28 July, 2035.
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 17 December, 2021
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer
Dosage: POWDER;INTRAVENOUS
ILLUCCIX family patents
